3D Medicines, Inc. (HK:1244) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
3D Medicines Inc. reports a significant 41.4% drop in revenue for the first half of 2024 compared to the same period in 2023, attributing the decline to intense competition in the PD-1/L1 market. Despite cost-cutting measures leading to reduced expenses in sales and research and development, the company faced a 40% decrease in total comprehensive loss. The financial health of the company shows a 19.8% reduction in cash and bank balances along with other financial assets.
For further insights into HK:1244 stock, check out TipRanks’ Stock Analysis page.